Pharmacology Watch
RSSArticles
-
Analysis Shows U.S. Drug Spending Far Exceeds All Other Nations
A recent study concluded there's no connection between research/development costs and prices, suggesting U.S. prescription drugs are priced primarily on the basis of what the market will bear.
-
FDA Actions
In this section: FDA approves generic influenza treatment; major pharma loses statin battle; FDA gives thumbs up to agonist to treat type 2 diabetes; agency green lights dry eye disease solution; and approves over-the-counter acne treatment.
-
Study: Knee Replacement Can Lead to Chronic Opioid Use
Total knee replacement is the surgical procedure most commonly associated with chronic opioid use in opioid-naïve patients.
-
Report: Certain Drugs Cause, Exacerbate Heart Failure
New recommendations for clinicians treating heart failure patients include comprehensive medication reconciliation, evaluating risks and benefits of every medication, and discontinuing medications when possible.
-
Top Pharmaceutical Company Suffers Blow After Major Drug Fails Phase III Trial
The checkpoint inhibitor nivolumab failed a Phase III trial as monotherapy in patients with previously untreated non-small cell lung cancer.
-
FDA Actions
In this section: The FDA approves new chronic hepatitis C treatment, greenlights a treatment course for primary biliary cirrhosis, and strengthens warning about the risk of acute kidney injury in several diabetes medications.
-
Patients Need More Education on Opioid Storage, Disposal
Recent survey discovers troubling trends.
-
Good News for Type 2 Diabetics
The rate of the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke among patients with type 2 diabetes mellitus was lower with liraglutide than with placebo.
-
Drug May Slow Renal Disease Progression
In patients with type 2 diabetes at high cardiovascular risk, empagliflozin was associated with slower progression of kidney disease and lower rates of clinically relevant renal events than was placebo when added to standard care.
-
Safe, Effective Alternatives to Warfarin
Non-vitamin K antagonist oral anticoagulants are safe and effective alternatives to warfarin in the routine care setting.